tiprankstipranks
Trending News
More News >

Halozyme announces EC approval of Bristol Myers’ Opdivo developed with Enhanze

Halozyme (HALO) announced that Bristol Myers Squibb (BMY) received European Commission, or EC, approval of a new Opdivo – nivolumab – subcutaneous formulation developed with Enhanze, Halozyme’s proprietary recombinant human hyaluronidase enzyme, for use across multiple adult solid tumors as monotherapy, monotherapy maintenance following completion of intravenous nivolumab plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib. The positive EC decision is supported by positive results from the Phase 3 CheckMate -67T trial. The approval by the EC is valid in all 27 member states of the European Union, as well as Iceland, Liechtenstein and Norway.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1